Skip to content
Main Navigation
About us
Company profile
Our values
Our strategy
Board of Directors
Senior management
Our history
Research and development
Technology platform
Therapeutic areas
Pipeline
Scientific papers and presentations
Partnering
Our approach
Our partnerships
Investors
Financial reports and presentations
Share information
Analyst coverage
Major shareholders
Financial calendar
Corporate governance
Corporate governance statements
Dividend policy
Annual general meeting
Articles of association
Safe harbour statement
Whistleblower policy
Risk management
Investor relations policy
ESG
Email alerts
Newsroom
Press Releases
Image library
Glossary
Email alerts
Careers
Life at Nykode
Meet us
Open positions
Search
Research and development
Scientific papers and presentations
Sharing our discoveries and developments in our tireless pursuit of breakthrough therapies
Newest first
Oldest first
Posters & Papers
Presentations
Search
Reset
12/11/2024
SITC 2024: A mRNA-LNP encoded APC-targeting neoantigen vaccine elicits stronger and broader T cell responses, and superior tumor control
07/11/2024
PEGS Europe 2024: APC-Targeted Vaccines Deliver Ag-specific Tolerance in Mouse Models of Autoimmunity
14/09/2024
ESMO 2024: A Phase 1/2a, Open-label, Dose-finding Trial to Evaluate Safety, Immunogenicity, and Anti-tumour Activity of VB10.16 in Combination with Pembrolizumab in Patients with Unresectable Recurrent or Metastatic HPV16-positive Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
20/06/2024
FOCIS 2024: Tolerogenic APC-targeted Vaccibody Vaccines Treat Disease in Mouse Models of Experimental Autoimmune Encephalomyelitis and Non-Obese Diabetes
11/06/2024
Nature Conferences: Cancer Immunotherapy – June 2024 | Targeted Delivery of Neoantigens to APCs using Vaccibodies Encoded in mRNA Results in Stronger and Broader T Cell Responses, and Improved Tumor Control
Pages:
1
2
3
4
5
6
7
8
9
Load more
Sorry, nothing found in this query
Privacy statement
Cookie policy
Disclaimer
